+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Nontuberculous Mycobacterial Infections Market 2024-2028

  • PDF Icon

    Report

  • 177 Pages
  • December 2023
  • Region: Global
  • TechNavio
  • ID: 5918139
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The nontuberculous mycobacterial infections market is forecasted to grow by USD 4.33 bn during 2023-2028, accelerating at a CAGR of 5.66% during the forecast period. The report on the nontuberculous mycobacterial infections market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing prevalence of NTM globally, rising geriatric population, and increasing awareness and diagnosis of NTM infections.

The nontuberculous mycobacterial infections market is segmented as below:

By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

By Product

  • Clarithromycin
  • Azithromycin
  • Rifampin
  • Rifabutin
  • Others

By Geography

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the growing adoption of precision medicine for treatment of ntm infections as one of the prime reasons driving the nontuberculous mycobacterial infections market growth during the next few years. Also, rise of novel drug delivery systems and growing focus on combination therapies will lead to sizable demand in the market.

The report on the nontuberculous mycobacterial infections market covers the following areas:

  • Nontuberculous mycobacterial infections market sizing
  • Nontuberculous mycobacterial infections market forecast
  • Nontuberculous mycobacterial infections market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading nontuberculous mycobacterial infections market vendors that include Abbott Laboratories, Astellas Pharma Inc., Cipla Ltd., Dr Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals Plc, Insmed Inc., Johnson and Johnson, Lupin Ltd., Merck and Co. Inc., Pace Biotech, Pfizer Inc., QIAGEN NV, Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd.. Also, the nontuberculous mycobacterial infections market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market by Geography
Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 06: Executive Summary - Chart on Market Segmentation by Product
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
4.1 Global nontuberculous mycobacterial infections market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global nontuberculous mycobacterial infections market 2018 - 2022 ($ billion)
4.2 Distribution Channel Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ billion)
4.3 Product Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Product Segment 2018 - 2022 ($ billion)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Distribution Channel
6.1 Market segments
Exhibit 30: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibit 31: Data Table on Distribution Channel - Market share 2023-2028 (%)
6.2 Comparison by Distribution Channel
Exhibit 32: Chart on Comparison by Distribution Channel
Exhibit 33: Data Table on Comparison by Distribution Channel
6.3 Hospital pharmacies - Market size and forecast 2023-2028
Exhibit 34: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 35: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 36: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
6.4 Retail pharmacies - Market size and forecast 2023-2028
Exhibit 38: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 39: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 40: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
6.5 Online pharmacies - Market size and forecast 2023-2028
Exhibit 42: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 43: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibit 44: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
6.6 Market opportunity by Distribution Channel
Exhibit 46: Market opportunity by Distribution Channel ($ billion)
Exhibit 47: Data Table on Market opportunity by Distribution Channel ($ billion)
7 Market Segmentation by Product
7.1 Market segments
Exhibit 48: Chart on Product - Market share 2023-2028 (%)
Exhibit 49: Data Table on Product - Market share 2023-2028 (%)
7.2 Comparison by Product
Exhibit 50: Chart on Comparison by Product
Exhibit 51: Data Table on Comparison by Product
7.3 Clarithromycin - Market size and forecast 2023-2028
Exhibit 52: Chart on Clarithromycin - Market size and forecast 2023-2028 ($ billion)
Exhibit 53: Data Table on Clarithromycin - Market size and forecast 2023-2028 ($ billion)
Exhibit 54: Chart on Clarithromycin - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Clarithromycin - Year-over-year growth 2023-2028 (%)
7.4 Azithromycin - Market size and forecast 2023-2028
Exhibit 56: Chart on Azithromycin - Market size and forecast 2023-2028 ($ billion)
Exhibit 57: Data Table on Azithromycin - Market size and forecast 2023-2028 ($ billion)
Exhibit 58: Chart on Azithromycin - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Azithromycin - Year-over-year growth 2023-2028 (%)
7.5 Rifampin - Market size and forecast 2023-2028
Exhibit 60: Chart on Rifampin - Market size and forecast 2023-2028 ($ billion)
Exhibit 61: Data Table on Rifampin - Market size and forecast 2023-2028 ($ billion)
Exhibit 62: Chart on Rifampin - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Rifampin - Year-over-year growth 2023-2028 (%)
7.6 Rifabutin - Market size and forecast 2023-2028
Exhibit 64: Chart on Rifabutin - Market size and forecast 2023-2028 ($ billion)
Exhibit 65: Data Table on Rifabutin - Market size and forecast 2023-2028 ($ billion)
Exhibit 66: Chart on Rifabutin - Year-over-year growth 2023-2028 (%)
Exhibit 67: Data Table on Rifabutin - Year-over-year growth 2023-2028 (%)
7.7 Others - Market size and forecast 2023-2028
Exhibit 68: Chart on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 69: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 70: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 71: Data Table on Others - Year-over-year growth 2023-2028 (%)
7.8 Market opportunity by Product
Exhibit 72: Market opportunity by Product ($ billion)
Exhibit 73: Data Table on Market opportunity by Product ($ billion)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 74: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 75: Chart on Market share by geography 2023-2028 (%)
Exhibit 76: Data Table on Market share by geography 2023-2028 (%)
9.2 Geographic comparison
Exhibit 77: Chart on Geographic comparison
Exhibit 78: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 79: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 80: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 81: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 83: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 84: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 85: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 87: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 88: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 89: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 91: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 92: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 93: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 95: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 96: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 97: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 UK - Market size and forecast 2023-2028
Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.9 Japan - Market size and forecast 2023-2028
Exhibit 103: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibit 104: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibit 105: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on Japan - Year-over-year growth 2023-2028 (%)
9.10 Germany - Market size and forecast 2023-2028
Exhibit 107: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 108: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 109: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 110: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.11 China - Market size and forecast 2023-2028
Exhibit 111: Chart on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 112: Data Table on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 113: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 114: Data Table on China - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity by geography
Exhibit 115: Market opportunity by geography ($ billion)
Exhibit 116: Data Tables on Market opportunity by geography ($ billion)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 117: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 118: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 119: Overview on factors of disruption
11.4 Industry risks
Exhibit 120: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 121: Vendors covered
12.2 Market positioning of vendors
Exhibit 122: Matrix on vendor position and classification
12.3 Abbott Laboratories
Exhibit 123: Abbott Laboratories - Overview
Exhibit 124: Abbott Laboratories - Business segments
Exhibit 125: Abbott Laboratories - Key news
Exhibit 126: Abbott Laboratories - Key offerings
Exhibit 127: Abbott Laboratories - Segment focus
12.4 Astellas Pharma Inc.
Exhibit 128: Astellas Pharma Inc. - Overview
Exhibit 129: Astellas Pharma Inc. - Product / Service
Exhibit 130: Astellas Pharma Inc. - Key news
Exhibit 131: Astellas Pharma Inc. - Key offerings
12.5 Cipla Ltd.
Exhibit 132: Cipla Ltd. - Overview
Exhibit 133: Cipla Ltd. - Business segments
Exhibit 134: Cipla Ltd. - Key news
Exhibit 135: Cipla Ltd. - Key offerings
Exhibit 136: Cipla Ltd. - Segment focus
12.6 Glenmark Pharmaceuticals Ltd.
Exhibit 137: Glenmark Pharmaceuticals Ltd. - Overview
Exhibit 138: Glenmark Pharmaceuticals Ltd. - Product / Service
Exhibit 139: Glenmark Pharmaceuticals Ltd. - Key offerings
12.7 Hikma Pharmaceuticals Plc
Exhibit 140: Hikma Pharmaceuticals Plc - Overview
Exhibit 141: Hikma Pharmaceuticals Plc - Business segments
Exhibit 142: Hikma Pharmaceuticals Plc - Key offerings
Exhibit 143: Hikma Pharmaceuticals Plc - Segment focus
12.8 Insmed Inc.
Exhibit 144: Insmed Inc. - Overview
Exhibit 145: Insmed Inc. - Product / Service
Exhibit 146: Insmed Inc. - Key offerings
12.9 Johnson and Johnson
Exhibit 147: Johnson and Johnson - Overview
Exhibit 148: Johnson and Johnson - Business segments
Exhibit 149: Johnson and Johnson - Key news
Exhibit 150: Johnson and Johnson - Key offerings
Exhibit 151: Johnson and Johnson - Segment focus
12.10 Lupin Ltd.
Exhibit 152: Lupin Ltd. - Overview
Exhibit 153: Lupin Ltd. - Product / Service
Exhibit 154: Lupin Ltd. - Key news
Exhibit 155: Lupin Ltd. - Key offerings
12.11 Pfizer Inc.
Exhibit 156: Pfizer Inc. - Overview
Exhibit 157: Pfizer Inc. - Product / Service
Exhibit 158: Pfizer Inc. - Key news
Exhibit 159: Pfizer Inc. - Key offerings
12.12 QIAGEN NV
Exhibit 160: QIAGEN NV - Overview
Exhibit 161: QIAGEN NV - Product / Service
Exhibit 162: QIAGEN NV - Key news
Exhibit 163: QIAGEN NV - Key offerings
12.13 Sanofi SA
Exhibit 164: Sanofi SA - Overview
Exhibit 165: Sanofi SA - Business segments
Exhibit 166: Sanofi SA - Key news
Exhibit 167: Sanofi SA - Key offerings
Exhibit 168: Sanofi SA - Segment focus
12.14 Sun Pharmaceutical Industries Ltd.
Exhibit 169: Sun Pharmaceutical Industries Ltd. - Overview
Exhibit 170: Sun Pharmaceutical Industries Ltd. - Product / Service
Exhibit 171: Sun Pharmaceutical Industries Ltd. - Key offerings
12.15 Teva Pharmaceutical Industries Ltd.
Exhibit 172: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 173: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 174: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 175: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 176: Teva Pharmaceutical Industries Ltd. - Segment focus
12.16 Viatris Inc.
Exhibit 177: Viatris Inc. - Overview
Exhibit 178: Viatris Inc. - Business segments
Exhibit 179: Viatris Inc. - Key news
Exhibit 180: Viatris Inc. - Key offerings
Exhibit 181: Viatris Inc. - Segment focus
12.17 Zydus Lifesciences Ltd.
Exhibit 182: Zydus Lifesciences Ltd. - Overview
Exhibit 183: Zydus Lifesciences Ltd. - Business segments
Exhibit 184: Zydus Lifesciences Ltd. - Key offerings
Exhibit 185: Zydus Lifesciences Ltd. - Segment focus
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 186: Inclusions checklist
Exhibit 187: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 188: Currency conversion rates for US$
13.4 Research methodology
Exhibit 189: Research methodology
Exhibit 190: Validation techniques employed for market sizing
Exhibit 191: Information sources
13.5 List of abbreviations
Exhibit 192: List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market by Geography
Exhibits 5: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibits 6: Executive Summary - Chart on Market Segmentation by Product
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibits 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibits 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 18: Historic Market Size - Data Table on global nontuberculous mycobacterial infections market 2018 - 2022 ($ billion)
Exhibits 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ billion)
Exhibits 20: Historic Market Size - Product Segment 2018 - 2022 ($ billion)
Exhibits 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
Exhibits 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
Exhibits 23: Five forces analysis - Comparison between 2023 and 2028
Exhibits 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits 26: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits 27: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits 28: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits 29: Chart on Market condition - Five forces 2023 and 2028
Exhibits 30: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibits 31: Data Table on Distribution Channel - Market share 2023-2028 (%)
Exhibits 32: Chart on Comparison by Distribution Channel
Exhibits 33: Data Table on Comparison by Distribution Channel
Exhibits 34: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibits 35: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibits 36: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 37: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 38: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibits 39: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibits 40: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 41: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 42: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibits 43: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
Exhibits 44: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 45: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 46: Market opportunity by Distribution Channel ($ billion)
Exhibits 47: Data Table on Market opportunity by Distribution Channel ($ billion)
Exhibits 48: Chart on Product - Market share 2023-2028 (%)
Exhibits 49: Data Table on Product - Market share 2023-2028 (%)
Exhibits 50: Chart on Comparison by Product
Exhibits 51: Data Table on Comparison by Product
Exhibits 52: Chart on Clarithromycin - Market size and forecast 2023-2028 ($ billion)
Exhibits 53: Data Table on Clarithromycin - Market size and forecast 2023-2028 ($ billion)
Exhibits 54: Chart on Clarithromycin - Year-over-year growth 2023-2028 (%)
Exhibits 55: Data Table on Clarithromycin - Year-over-year growth 2023-2028 (%)
Exhibits 56: Chart on Azithromycin - Market size and forecast 2023-2028 ($ billion)
Exhibits 57: Data Table on Azithromycin - Market size and forecast 2023-2028 ($ billion)
Exhibits 58: Chart on Azithromycin - Year-over-year growth 2023-2028 (%)
Exhibits 59: Data Table on Azithromycin - Year-over-year growth 2023-2028 (%)
Exhibits 60: Chart on Rifampin - Market size and forecast 2023-2028 ($ billion)
Exhibits 61: Data Table on Rifampin - Market size and forecast 2023-2028 ($ billion)
Exhibits 62: Chart on Rifampin - Year-over-year growth 2023-2028 (%)
Exhibits 63: Data Table on Rifampin - Year-over-year growth 2023-2028 (%)
Exhibits 64: Chart on Rifabutin - Market size and forecast 2023-2028 ($ billion)
Exhibits 65: Data Table on Rifabutin - Market size and forecast 2023-2028 ($ billion)
Exhibits 66: Chart on Rifabutin - Year-over-year growth 2023-2028 (%)
Exhibits 67: Data Table on Rifabutin - Year-over-year growth 2023-2028 (%)
Exhibits 68: Chart on Others - Market size and forecast 2023-2028 ($ billion)
Exhibits 69: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
Exhibits 70: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibits 71: Data Table on Others - Year-over-year growth 2023-2028 (%)
Exhibits 72: Market opportunity by Product ($ billion)
Exhibits 73: Data Table on Market opportunity by Product ($ billion)
Exhibits 74: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 75: Chart on Market share by geography 2023-2028 (%)
Exhibits 76: Data Table on Market share by geography 2023-2028 (%)
Exhibits 77: Chart on Geographic comparison
Exhibits 78: Data Table on Geographic comparison
Exhibits 79: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibits 80: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibits 81: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibits 82: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibits 83: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibits 84: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibits 85: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 86: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 87: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibits 88: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibits 89: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 90: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 91: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibits 92: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibits 93: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 94: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 95: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibits 96: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibits 97: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibits 98: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibits 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibits 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibits 101: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibits 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
Exhibits 103: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibits 104: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibits 105: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibits 106: Data Table on Japan - Year-over-year growth 2023-2028 (%)
Exhibits 107: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibits 108: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibits 109: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 110: Data Table on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 111: Chart on China - Market size and forecast 2023-2028 ($ billion)
Exhibits 112: Data Table on China - Market size and forecast 2023-2028 ($ billion)
Exhibits 113: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibits 114: Data Table on China - Year-over-year growth 2023-2028 (%)
Exhibits 115: Market opportunity by geography ($ billion)
Exhibits 116: Data Tables on Market opportunity by geography ($ billion)
Exhibits 117: Impact of drivers and challenges in 2023 and 2028
Exhibits 118: Overview on Criticality of inputs and Factors of differentiation
Exhibits 119: Overview on factors of disruption
Exhibits 120: Impact of key risks on business
Exhibits 121: Vendors covered
Exhibits 122: Matrix on vendor position and classification
Exhibits 123: Abbott Laboratories - Overview
Exhibits 124: Abbott Laboratories - Business segments
Exhibits 125: Abbott Laboratories - Key news
Exhibits 126: Abbott Laboratories - Key offerings
Exhibits 127: Abbott Laboratories - Segment focus
Exhibits 128: Astellas Pharma Inc. - Overview
Exhibits 129: Astellas Pharma Inc. - Product / Service
Exhibits 130: Astellas Pharma Inc. - Key news
Exhibits 131: Astellas Pharma Inc. - Key offerings
Exhibits 132: Cipla Ltd. - Overview
Exhibits 133: Cipla Ltd. - Business segments
Exhibits 134: Cipla Ltd. - Key news
Exhibits 135: Cipla Ltd. - Key offerings
Exhibits 136: Cipla Ltd. - Segment focus
Exhibits 137: Glenmark Pharmaceuticals Ltd. - Overview
Exhibits 138: Glenmark Pharmaceuticals Ltd. - Product / Service
Exhibits 139: Glenmark Pharmaceuticals Ltd. - Key offerings
Exhibits 140: Hikma Pharmaceuticals Plc - Overview
Exhibits 141: Hikma Pharmaceuticals Plc - Business segments
Exhibits 142: Hikma Pharmaceuticals Plc - Key offerings
Exhibits 143: Hikma Pharmaceuticals Plc - Segment focus
Exhibits 144: Insmed Inc. - Overview
Exhibits 145: Insmed Inc. - Product / Service
Exhibits 146: Insmed Inc. - Key offerings
Exhibits 147: Johnson and Johnson - Overview
Exhibits 148: Johnson and Johnson - Business segments
Exhibits 149: Johnson and Johnson - Key news
Exhibits 150: Johnson and Johnson - Key offerings
Exhibits 151: Johnson and Johnson - Segment focus
Exhibits 152: Lupin Ltd. - Overview
Exhibits 153: Lupin Ltd. - Product / Service
Exhibits 154: Lupin Ltd. - Key news
Exhibits 155: Lupin Ltd. - Key offerings
Exhibits 156: Pfizer Inc. - Overview
Exhibits 157: Pfizer Inc. - Product / Service
Exhibits 158: Pfizer Inc. - Key news
Exhibits 159: Pfizer Inc. - Key offerings
Exhibits 160: QIAGEN NV - Overview
Exhibits 161: QIAGEN NV - Product / Service
Exhibits 162: QIAGEN NV - Key news
Exhibits 163: QIAGEN NV - Key offerings
Exhibits 164: Sanofi SA - Overview
Exhibits 165: Sanofi SA - Business segments
Exhibits 166: Sanofi SA - Key news
Exhibits 167: Sanofi SA - Key offerings
Exhibits 168: Sanofi SA - Segment focus
Exhibits 169: Sun Pharmaceutical Industries Ltd. - Overview
Exhibits 170: Sun Pharmaceutical Industries Ltd. - Product / Service
Exhibits 171: Sun Pharmaceutical Industries Ltd. - Key offerings
Exhibits 172: Teva Pharmaceutical Industries Ltd. - Overview
Exhibits 173: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibits 174: Teva Pharmaceutical Industries Ltd. - Key news
Exhibits 175: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibits 176: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibits 177: Viatris Inc. - Overview
Exhibits 178: Viatris Inc. - Business segments
Exhibits 179: Viatris Inc. - Key news
Exhibits 180: Viatris Inc. - Key offerings
Exhibits 181: Viatris Inc. - Segment focus
Exhibits 182: Zydus Lifesciences Ltd. - Overview
Exhibits 183: Zydus Lifesciences Ltd. - Business segments
Exhibits 184: Zydus Lifesciences Ltd. - Key offerings
Exhibits 185: Zydus Lifesciences Ltd. - Segment focus
Exhibits 186: Inclusions checklist
Exhibits 187: Exclusions checklist
Exhibits 188: Currency conversion rates for US$
Exhibits 189: Research methodology
Exhibits 190: Validation techniques employed for market sizing
Exhibits 191: Information sources
Exhibits 192: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global nontuberculous mycobacterial infections market: Abbott Laboratories, Astellas Pharma Inc., Cipla Ltd., Dr Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals Plc, Insmed Inc., Johnson and Johnson, Lupin Ltd., Merck and Co. Inc., Pace Biotech, Pfizer Inc., QIAGEN NV, Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd..

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is growing adoption of precision medicine for treatment of NTM infections.'

According to the report, one of the major drivers for this market is the growing prevalence of NTM globally.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • Cipla Ltd.
  • Dr Reddys Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals Plc
  • Insmed Inc.
  • Johnson and Johnson
  • Lupin Ltd.
  • Merck and Co. Inc.
  • Pace Biotech
  • Pfizer Inc.
  • QIAGEN NV
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Ltd.

Related Topics

Related Reports

Nontuberculous Mycobacterial Infection Global Market Report 2024 - Product Image

Nontuberculous Mycobacterial Infection Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease Drugs Market 2024-2028 - Product Image

Chronic Obstructive Pulmonary Disease Drugs Market 2024-2028

  • Report
  • 168 Pages
  • Global
From
Sarcoidosis Therapeutics Market 2024-2028 - Product Image

Sarcoidosis Therapeutics Market 2024-2028

  • Report
  • 158 Pages
  • Global
From
Nontuberculous Mycobacterial (NTM) Infections - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Nontuberculous Mycobacterial (NTM) Infections - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 101 Pages
  • Global
From
Onychomycosis Treatment Global Market Report 2024 - Product Image

Onychomycosis Treatment Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.